MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2019 International Congress

    Successful late rehabilitation based on botulinum therapy

    T. Kuznetsova, A. Svetkina (Samara, Russian Federation)

    Objective: Hemiparesis of various severity is the most common stroke side effect. On average 30-40% of stroke survivors develop post-stroke spasticity. The best neuroplasticity enabling…
  • 2019 International Congress

    Training and Usage of Botulinum Neurotoxin-A Guided Injection in Cervical Dystonia & Spastic Paresis: results from the INPUT survey

    R. Bhidayasiri, K. Bhatia, LJ. Jacinto, TM. Chung, A. Fulford-Smith, C. Colosimo (Roma, Italy)

    Objective: To describe the current situation of training and practices among physicians using guidance techniques for botulinum neurotoxin-A (BoNT-A) injectionsin the treatment of Cervical Dystonia…
  • 2019 International Congress

    Ixcellence Network®, an International Innovative Educational Programme To Improve Cervical Dystonia And Spastic Paresis Management: Feedback survey from 839 attendees

    C. Colosimo, TM. Chung, LJ. Jacinto, K. Bhatia, A. Fulford-Smith, R. Bhidayasiri (Roma, Italy)

    Objective: To assess the Ixcellence Network® training programme educative quality and impact on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis…
  • 2018 International Congress

    5 Years’ Experience of Ixcellence Network®, an International Innovative Educational Program to improve Cervical Dystonia and Spastic paresis Management Practices

    C. Colosimo, T.M. Chung, L.J. Jacinto, K. Bahtia, T. Landreau, R. Bhidayasiri (Roma, Italy)

    Objective: To describe the impact of the Ixcellence® Network training program on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis (SP).…
  • 2018 International Congress

    First Results from the Ixcellence Network® Survey: Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis

    R. Bhidayasiri, K. Bahtia, L.J. Jacinto, TM. Chung, T. Landreau, C. Colosimo (Bangkok, Thailand)

    Objective: To describe the current situation of training and practices among physicians using botulinum neurotoxin-A (BoNT-A) injections in the treatment of Cervical Dystonia (CD) and…
  • 2018 International Congress

    “Appropriate Doses Treatment” of IncobotulinumtoxinA in spasticity

    G. Ianieri, R. Marvulli (Bari, Italy)

    Objective: The aim of this study is to object the efficiency and safety of 100 to 1000 units botulinum toxin treatment with modulation of spasticity…
  • 2018 International Congress

    Evaluation of Effectiveness and Safety of Botulinum Toxin Type-A (BTX-A) for Chronic Focal Post-Stroke Upper Limb Spasticity in Indian Stroke Patients

    L. Basumatary (Guwahati, India)

    Objective: To evaluate the effectiveness and safety of Botulinum Toxin Type-A (BTX-A) for the treatment chronic focal post-stroke upper limb spasticity in Indian stroke patients.…
  • 2017 International Congress

    Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

    R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

    Objective: To identify the epidemiological profile of patients treated with botulinum toxin type A (BTA) in a tertiary clinic in Brazil. Background: BTA is used to…
  • 2017 International Congress

    A Comparison of Muscular Atrophy Between Botulinum Toxin Types A and B

    F. Amjad, F. Pagan, A. Lax, C. Moussa (Washington DC, DC, USA)

    Objective: To compare and quantify the degree of muscular atrophy (MA) in botulinum toxin (BT) type A (Botox) and type B (Myobloc). A secondary endpoint…
  • 2017 International Congress

    The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results

    G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)

    Objective: To evaluate the 1-year interim onabotulinumtoxinA safety, effectiveness, and exploratory treatment utilization data from the ASPIRE study. Background: OnabotulinumtoxinA treatment for patients with spasticity…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley